Navigation Links
Milestone Scientific's STA(TM) System Wins 2008 Medical Design Excellence Award

LIVINGSTON, N.J., April 21 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that Medical Device & Diagnostic Industry (MD&DI) magazine has distinguished the STA(TM) System as a winner of the 2008 Medical Design Excellence Award (MDEA) in the "dental instruments, equipment and supplies" product category. Of the 33 products to receive an MDEA this year, Milestone's STA System was one of only two winning products that serve dental practitioners.

Sponsored by MD&DI, the Medical Design Excellence Awards (MDEA) competition is the premier awards program for the medical technology community. It recognizes the achievements of medical device manufacturers, their suppliers and the many people behind the scenes -- engineers, scientists, designers and clinicians -- who are responsible for the groundbreaking innovations that are changing the face of healthcare. MDEA-winning entries excel in the areas of product innovation, design and engineering achievement, end-user benefit and cost effectiveness in manufacturing and healthcare delivery. To select the 2008 winners, a comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third party jurors with expertise in biomedical engineering, human factors, medicine and diagnostics. The 2008 jury selected 33 winners in 10 medical product categories.

"We are delighted that our award winning STA System continues to be recognized by leading industry publications as the best of the best in dental innovations," stated Joe Martin, Chief Executive Officer of Milestone. In July 2007, noted industry publication Dentistry Today featured the STA System as one of the Top 100 Products in 2007. "These industry acknowledgements are helping Milestone and its global distributor network to accelerate industry adoption of the STA System as the new standard of care for dental injections."

"The team at Milestone Scientific is honored by this prestigious award. Over the years, our technology has been validated in numerous clinical studies published in professional journals documenting positive clinical results. This award, however, represents a new category of validation for us, so we are very pleased indeed," noted Dr. Mark Hochman, Director of Clinical Affairs of Milestone and STA System inventor.

The award ceremony will be held June 4, 2008 during the Medical Design and Medical Manufacturing East 2008 Conference and Exposition at the Jacob K. Javits Convention Center in New York City. For more information about the 2008 MDEA award winners, please visit

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) (Single Tooth Anesthesia) System is a computer-controlled local anesthesia delivery system which uses this technology to provide dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2007. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategy Officer

407-585-1080 or via email at

SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: